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Abstract
Soft tissue tumors represent a group of neoplasia with different histologic and biological presentations varying from
benign, locally confined to very aggressive and metastatic tumors. The molecular mechanisms responsible for such
differences are still unknown. The understanding of these molecular alterations mechanismwill be critical to discrimi-
nate patients who need systemic treatment from those that can be treated only locally and could also guide the de-
velopment of new drugs’ against this tumors. Using 102 tumor samples representing a large spectrum of these
tumors, we performed expression profiling and defined differentially expression genes that are likely to be involved
in tumors that are locally aggressive and in tumors with metastatic potential. We described a set of 12 genes
(SNRPD3,MEGF9, SPTAN-1, AFAP1L2, ENDOD1, SERPIN5, ZWINTAS, TOP2A, UBE2C, ABCF1,MCM2, and ARL6IP5)
showing opposite expression when these two conditions were compared. These genes are mainly related to cell-cell
and cell–extracellular matrix interactions and cell proliferation and might represent helpful tools for a more precise
classification and diagnosis as well as potential drug targets.
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Introduction
Soft tissue tumors are a heterogeneous group of mesenchymal tumors
with diverse histologic presentation and clinical behavior [1]. Histologi-
cally, soft tissue tumors are classified in more than 50 subtypes, based
on their cellular differentiation and morphologic findings. In this study,
peripheral neural tumors were also included because their morphology,
clinical behavior, and treatment are similar to soft tissue mesenchymal
tumors and they are also considered soft tissue tumors.
According to their biological behavior, they can be grouped into
three major categories, benign mesenchymal tumors (BMTs), tumors
with local aggressiveness but with no metastatic potential, and sarcomas
(malignant mesenchymal tumors [MMTs]) that have both local ag-
gressiveness and metastatic potential. The latter group can be further
subdivided as low-, intermediate-, or high-grade tumors according
to classifications of the National Cancer Institute and Fédération
Nationale des Centres de Lutte Contre le Cancer. The National Cancer
Institute system uses a combination of histologic type, cellularity, pleo-
morphism, and mitotic rate [2]. The Fédération Nationale des Centres
de Lutte Contre le Cancer system is based on a score by evaluating three
parameters, namely tumor differentiation, mitotic rate, and amount of
necrosis. The score is attributed independently to each parameter, and
the grade is a result of its adding [3].
At the molecular level, sarcomas can be characterized by the presence
or the absence of tumor-specific mutations. For instance, alveolar rhab-
domyosarcomas are characterized by t(1;13) (PAX7;FKHR) or t(2;13)
(PAX3;FKHR) translocations, whereas synovial sarcomas have specific
t(X;18) (SSX;SYT ) translocation. In contrast, leiomyosarcomas and
pleomorphic sarcomas lack specific chromosome alterations [4].
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Sarcomas represent approximately 1% of adult malignancies but,
despite this low incidence, are often of poor prognosis, at a discrepancy
with their benign counterpart such as schwannomas, lipomas, and
leiomyomas that are usually well-circumscribed tumors, with no local
aggressiveness and without metastatic potential. In between these two
extremes, there are some subtypes of mesenchymal tumors that have
characteristics of both groups. They are locally aggressive but lack
metastatic potential. One classic example is desmoids tumors, also
known as desmoid-type fibromatosis (DTF). They are clonal tumors,
with fibroblastic proliferation and local aggressiveness but without
metastatic potential. They occur with higher frequency in chest and
abdominal wall, thigh, and head and neck region. Local recurrence is
frequent, and they can be fatal owing to local effects, especially in the
head and neck region [5].
Whereas tumor size and histologic features are the best prognostic
factors available for mesenchymal tumors, little is known about molec-
ular alterations that could contribute to the understanding of cell origin,
malignant transformation, and tumor biology. Also, few molecular
markers were identified as having diagnostic and prognostic values.
Gastrointestinal stromal tumors (GISTs) are one of the few successful
examples of mesenchymal tumors in which the molecular events related
to malignant transformation are well established. These tumors usually
have an activating mutation of C-Kit gene and can be treated with
imatinib mesylate, a tyrosine kinase inhibitor [6]. Another example
of a gene that was recently described as a sensitive and specific immu-
nohistochemical marker for synovial sarcoma is TLE1 [7]. TLE pro-
teins are transcriptional corepressors that inhibit Wnt signaling and
have a role in repressing differentiation. Measurement of TLE1 expres-
sion might have applications for diagnosis and eventually for the under-
standing of tumor biology.
Several others studies using microarray technology had been reported
mainly to describe gene expression signature associated with histologic
differentiation or outcome in specific histologic subtypes [8–16].
It is clear that sarcomas have distinct pathways related to malignant
transformation and cellular differentiation and some of molecular alter-
ations can be pinpointed to specific chromosomal translocations that
are pathognomonic for specific tumors. Nevertheless, tumors arising
from distinct pathways and/or cell types can be grouped as a function
of their biological behavior and defined by their histologic grade of
malignancy. Importantly, tumors with similar behavior are treated simi-
larly. Furthermore, most sarcomas have metastatic dissemination
through blood vessels with exception for those with epithelial differen-
tiation that can also have lymphatic dissemination. Because our goal is
the understanding of biological behavior, rather than sarcogenesis, we
grouped samples regardless of histologic classification, favoring meta-
static potential. In an effort to identify genes that could be implicated
in aggressiveness and/or metastatic behavior of sarcomas, we compared
the expression profile of a set of 102 samples representing benign soft
tissue tumors, DTF, and sarcomas. Here, we describe a set of altered
genes that, on the basis of their function, are candidates for playing a
role in the biology of soft tissue tumors and, hence, are potential drug
targets. These genes might also serve as prognostic factors.
Materials and Methods
Patients and Samples
Patients were recruited at Hospital do Cancer AC Camargo (São
Paulo/Brazil) during an 8-year period (1997-2004). All patients
signed a preinformed consent and the study was approved by our in-
ternal review board (664/04). Tissue samples were provided by the
ACCamargoHospital Tumor Bank. Tissue samples obtained by surgery
were snap frozen in liquid nitrogen, whereas biopsy samples were col-
lected in RNAlater (Ambion, Austin, TX). All samples were then stored
at −140°C until further processing. At the time of RNA extraction,
diagnosis was reconfirmed by hematoxylin and eosin staining. Frozen
samples were hand-dissected for removal of infiltrating inflammatory
cells and for enrichment of tumor. For proper tumor classification, im-
munohistochemistry using a panel of antibodies was done in the cor-
responding paraffin-formalin–embedded blocks. A detailed description
of the 102 samples is presented in Table W1. For immunohistochemis-
try, we evaluated a total of 253 cases, including 101 fibromatosis,
38 synovial sarcomas, 37 leiomyosarcomas, 33 pleomorphic sarcomas,
10 fibrosarcomas, 9 liposarcomas, 7 malignant peripheral nerve sheet
tumors, 6 GISTs, 6 neurofibromas, 4 alveolar soft part sarcomas, 4 leio-
myomas, and 4 schwannomas, retrieved from archived samples.
Extraction, Amplification, and Labeling of the Amplified RNA
Total RNAwas extracted using Trizol (Life Technologies, Inc, Grand
Island, NY) and amplified by a T7-based protocol [17]. As described
by Pollack [18], all samples were compared with a reference RNA. We
used a pool of RNA representing equal total RNA concentration for
15 human cell lines. For replica hybridizations with dye-swap, ampli-
fied RNA (3 mg) was added to synthetic antisense RNA corresponding
to internal controls, and labeled indirectly, with either Alexa Fluor 555 or
Alexa Fluor 647 (catalog no. A32757;Molecular Probes, Carlsbad, CA).
Hybridization and Scanning of Complementary
DNA Microarray
Glass arrays containing 4800 spots, of which 4566 are unique com-
plementary DNA (cDNA) sequences, were prepared in our laboratory
with the aid of the Flexys robot (Genomic Solutions, UK [23]). Detailed
descriptions are available at Gene Expression Omnibus data repository
under accession number GPL1930, and the accession number for raw
data is GSE14541 (http://www.ncbi.nlm.nih.gov/projects/geo).
Prehybridization, hybridization, and washing were performed as pre-
viously described [17] and slides were scanned on a confocal laser scan-
ner (ScanArray Express; PerkinElmer Life Sciences, Waltham, MA).
Data were extracted with ScanArray Express software (PerkinElmer Life
Sciences) using the histogram method.
Quantitative Polymerase Chain Reaction
For validation of array data, we used 27 samples also used in array
analysis (5 BMTs, 6 DTFs, and 16 MMTs) plus 14 independent
samples (12 BMTs and 2 DTFs). A detailed description of samples is
presented in Table W1.
Aliquots of 2μg of total RNAwere reverse-transcribed in the presence
of 500 ng of oligo(dT15) in a final reaction volume of 20 μl using
Impron II Reverse Transcriptase System (Promega, Madison, WI).
Primer pairs for real-time polymerase chain reaction (PCR) were deter-
mined with the aid of Primer Express software 3.0 (Applied Biosciences,
Carlsbad, CA) using default parameters. The primer sets are described in
TableW2. Reactions were performed in the presence of 10 ng of cDNA
product using SYBRGreen Master Mix system according to the manu-
facturer’s instructions. Reactions were performed in duplicate on an
ABI PRISM 7300 Sequence Detection System (Applied Biosystems,
Carlsbad, CA) and analyzed with Sequence Detection Software (version
2.3). The C t values were transformed into units using comparative C t
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method [19], and the normalization factor for each sample was calculated
using Genorm software based on the expression level of endogenous
HMBS, BCR2, and HPRT [20]. Once normalized, data were statisti-
cally analyzed by GraphPad PRISM 4 Software (La Jolla, CA) using
Mann-Whitney.
Tissue Microarray and Immunostaining Procedure
One cylinder of 1 mm was obtained from each tumor to build the
tissue microarray (TMA; Beecher Instruments, Sun Prairie, WI) as pre-
viously described [21]. Sequential sections (4 mm thick) of the TMA
were used to immunohistochemical detection of proteins ARL6IP5
(Gene Way Biotech, Inc, San Diego, CA; working dilution 1:400),
AFAP1l2 (Protein Tech Group, Inc, Chicago, IL; working dilution
1:100), MCM2 (Protein Tech Group, Inc; working dilution 1:100)
and SNRPD3 (Protein Tech Group, Inc; working dilution 1:100).
The second-generation biotin-free polymeric system Advance (DAKO,
Carpinteria, CA) was used for staining. All immunohistochemistry
reactions were performed simultaneously to avoid any bias in the results
due to the order of testing or differences in environmental conditions.
Immunostaining Analysis
All slides submitted to immunohistochemistry were labeled for
blinded automated examination. All slides were digitalized using the
Aperio System (Vista, CA), and the images provided by the software
were exhibited on an LCDmonitor under standardized contrast, focus,
saturation, and white balance. Automated image quantification was
performed using the images obtained. To evaluate the staining intensity,
the Aperio image analysis system was used. This software identifies
the immunohistochemical staining to be quantified by minimizing
background-staining artifacts through image filters. Because the soft-
ware recognizes positive nuclei or cytoplasm staining of all different
intensities, the quantificationwas processed in each TMA spot automati-
cally by the software. Numerical data of staining intensity average
corresponding to each spot were exported to a Microsoft Excel (Seattle,
WA) file for further statistical analysis. The software Prism 5 for
Windows, version 5.02 (La Jolla, CA), was used for the immuno-
histochemistry analysis. The D’Agostino normality test was used to
verify the data distribution pattern of each group. The t test was used
when comparing two groups of normal distribution and the Mann-
Whitney test was used when comparing two groups of nonparametric
distribution to evaluate the differences between them.
Statistical Analysis
For data analysis, we used R (http://cran.r.project.org/), an open-
source interpreted computer language for statistics, computation and
graphics, and packages from the Bioconductor project (http://www.
bioconductor.org), such as maigesPack. After image acquisition and
quantification, spots with signal lower or equal to background were
excluded from the analysis. Background-subtracted spot intensities were
normalized by loess, using span equal to 0.4 and degree equal to 2. For
identification of differentially expressed genes, the nonparametric test
Mann-Whitney-Wilcoxon was applied, and P values were corrected
by Bonferroni [22] and false discovery rate [23]. Using pairwise com-
parisons, we searched for differentially expressed genes consider-
ing three samples groups: BMTs, DTFs, and sarcomas (MMT). First,
we compared BMTs versus DTFs (comparison A), followed by sarco-
mas versus DTFs (comparison B), and, finally, BMTs versus sarcomas
samples (comparison C). For the last comparison, we ranked the genes
according to their significance and observed their behavior on the first
two comparisons.
Results
Aiming to identify genes potentially associated with local aggressiveness
and metastatic potential of mesenchymal tumors, we determined the
expression profile of a total of 102 fresh tumor samples. On the basis
of their biological behavior and histopathology, tumors were grouped
into three major categories: BMTs, tumors with local aggressiveness but
with no metastatic potential, and sarcomas that have both local aggres-
siveness and metastatic potential (Figure 1). Next, we searched for
differentially expressed genes in each of the three pairwise comparisons.
A complete list with fold change and corrected P values is presented as
Table W3.
Figure 1. Histopathologic representation of diverse biological behavior in mesenchymal tumors (H&E staining).
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The genes involved in local aggressiveness could be interpreted as
genes that are differently expressed between BMTs and DTF and also
between BMTs and sarcomas, that is, differentially expressed in both
comparisons C and A. The search for genes related to metastatic
potential, using the same approach, could be interpreted as genes dif-
ferentially expressed in comparison B, between sarcomas and DTF, as
well as in comparison C, between BMTs and sarcomas.
For comparison C, we ranked the genes according to their statistical
significance and observed their behavior on comparisons A and B. We
noticed that the first 12 genes of this ranking showed a dichotomy when
comparison A and B were made. Genes that were upregulated in Awere
downregulated in B and vice versa. Moreover, when plotted in a three-
dimensional space according to their fold change, these could precisely
discriminate between samples fromA or B groups (Figure 2). Therefore,
we focused further analysis on these genes. It is noteworthy that selection
of these twelve genes was not based on differential expression but rather,
on this opposite behavior in A and B comparisons. Hence, it is appro-
priate to consider their nominal P value. The genes related to local
aggressiveness are SNRPD3,MEGF9, SPTAN-1,AFAP1L2, ENDOD1,
and SERPIN5. The genes related to metastatic potential are ZWINTAS,
TOP2A, UBE2C, ABCF1, MCM2, and ARL6IP5.
Differential Expression as a Function of Tumor Types: BMT,
DTF, and MMT
The expression levels of these 12 genes in each tumor type (BMT,
DTF, and MMT) are presented in Figure 3A, for genes potentially in-
volved in local aggressiveness, and in Figure 3B, for genes potentially
involved in metastasis. We also represented, by box plot, the expression
profile of these 12 genes as a function of tumor types BMT, DTF and
for MMTwe segregate samples representing sarcomas of low, interme-
diate, or high grade (Figure W1). The same distribution was observed
in Figure 3, and for some genes, such as ARLP6IP5 and TOP2A, there
is a gradual change from benign tumors to sarcomas of high grade. For
others, such as SERPIN5 and SNRPD3, there is a single-step change,
suggesting that, if functionally involved, they would be associated with
aggressiveness, either locally or at a distance.
Validation of Differential Expression
Validation of observed changes was done by quantitative PCR (Q-
PCR) using RNA from samples used for the expression profile as well
as from independent samples. For genes potentially related to local ag-
gressiveness, we confirmed the differential expression for AFAP1L2,
MEGF9, ENDOD1, and SERPIN5 (Figure 4A).
For genes potentially related to metastasis, we confirmed the differ-
ential expression of UBE2C, ZWINTAS,MCM2, and TOP2A as being
higher expressed in samples representing MMT compared with non-
metastatic BMT and DTF samples (Figure 4B).
Validation of Protein Levels
We were able to determine protein levels for 4 of the 12 identified
genes (MCM2, ARLP6, AFAP1, and SNRPD3). We have compared
their protein expression levels by separating samples into the following
groups: BMTs (leiomyomas, neurofibromas, and schwannomas),
DTFs, and MMTs (synovial sarcomas, leiomyosarcomas, pleomorphic
sarcomas, fibrosarcomas, liposarcomas,malignant peripheral nerve sheet
tumor, GIST, and alveolar soft part sarcomas). ForMCM2 and ARLP6
analysis (genes related to metastatic potential), we compared BMT plus
DTF versusMMT, and for AFAP1 and SNRPD3 (genes related to local
aggressiveness), we compared BMT versus DTF plus MMT.
We found a higher expression ofMCM2 in the BMTandDTF group
in comparison with the MMT group (P < .001). For ARLP6, there was
also a significantly higher protein expression in the BMT and DTF
Figure 2. Three-dimensional scatter plot representing the expression of genes associated to local aggressiveness and metastasis. For each
gene, we determined their nominal P values (Wilcoxon test, −log10) and plotted in a three-dimensional scatter plot. In red are the genes
associated to local aggressiveness and in green are the genes associated to metastasis.
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Figure 3. Representative box plot showing the expression (fold change) of the six genes related to local aggressiveness (AFAP1L2,MEGF9,
ENDOD1, SERPIN5, SNRPD3, and SPTAN; A) and the six genes related tometastatic potential (ABCF1,MCM2,ARL6IP5, TOP2A,UBE2C, and
ZWINTAS; B) in BMTs, DTFs, and MMTs. For all genes, the value for each pairwise comparison is described in Table W3.
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group when compared to the MMT group (P < .0001). Conversely,
there was a higher protein expression of SNRPD3 in DTF and MMT
than in BMT (P = .013). There was no significant difference expression
of AFAP1 between the two groups (P = .343; Figure 5).
Discussion
Soft tissue tumors encompass a myriad of different tumors with diverse
cellular differentiation as well as different biological behavior. Although
arising from distinct genetic alterations and/or signaling pathways, they
can be grouped on the basis of their biological behavior, considering
their local aggressiveness and metastatic potential. The molecular events
related to these differences are yet unknown. The understanding of
these mechanisms is important in discriminating those patients who
will need systemic treatment from those that can be treated only locally.
More than that, it also could guide for the development new drugs.
In this study, we compared the expression profile of 102 tumor
Figure 4. Validation by Q-PCR of the genes related to local aggressiveness (A) andmetastasis (B). Total RNA used for Q-PCRwas performed
using SYBR green. P values were calculated by Mann-Whitney.
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samples representing soft tissue tumors. We identified a group of six
genes that could be either markers or functional related to local aggres-
siveness (SNRPD3, MEGF9, SPTAN-1, AFAP1L2, ENDOD1, and
SERPIN5) and another group of six genes that could be related to
metastatic potential (ZWINTAS, TOP2A, UBE2C, ABCF1, MCM2,
and ARL6IP5).
As recently reviewed by Chiang and Massagué [24], it is likely that
cancer cells accumulate malignant function to promote expansion of
the primary tumor, and this cumulative strategy might be necessary
but not sufficient for the development of metastasis. Usually, initia-
tion of metastasis requires alterations in genes related to local inva-
sion (motility and extracellular matrix remodeling), angiogenesis, and
epithelial-to-mesenchymal transition. For the establishment of me-
tastasis, genes functionally related to vascular remodeling, immune
evasion followed by alterations in organ-specific function might need
to be altered. The set of genes that we identified in this article seems to
follow this rationale. SERPIN5, SPTAN-1, and MEGF9 are involved
in cell invasion, tissue destruction, and cell motility, respectively,
whereasUBE2C, ARL6IP5,MCM2, TOP2A, and ABCF1 are involved
in increase of metabolism, cell migration, cell cycle, cell proliferation,
and malignant transformation, respectively. AFAP1L2, SNRPD3,
ZWINTAS, and ENDOD1 have never been related to cancer before
but might play a role in tumor biology.
Since 2002, many groups reported the identification of predictors
of tumor behavior such as responsiveness, local recurrence, or meta-
static potential [24–30]. For example, van ’t Veer et al. [25] defined a
set of 71 genes that, according to their expression profile, could de-
fine the need for adjuvant in patients with early-stage breast carcinoma.
Also, Ramaswamy et al. [26] compared gene expression profile of
primary adenocarcinomas and unmatched metastasis and revealed
that primary and metastatic tumors share a set of genes commonly
altered suggesting that aggressiveness is an early event during tu-
mor development.
In sarcomas, the pattern of metastasis differs from carcinomas. Sarco-
mas rarely metastasize to lymph nodes, and the most frequent sites of
metastasis are lungs follow by liver (hematogenic metastasis). Because
soft tissue sarcomas are of mesodermal origin, probably the molecular
events related to metastasis of these tumors may be distinct from tumors
of other embryonic origins.
There are very few reports correlating gene expression profile and
metastasis in sarcomas. Lee et al. [27] have identified a gene expression
signature associated with metastasis in leiomyosarcoma that allowed
prediction of the future development of metastases. The most dis-
criminating genes are those encoding for proteins involved in tumor
development and invasion, especially cell growth and transition
through cell cycle. Ren et al. [28] identified a 92-gene signature in
Figure 5. Representative box plot showing the protein expression of the two proteins related to local aggressiveness (AFAP1L2 and
SNRPD3) and two proteins related to metastatic potential (MCM2 and ARL6IP5) in BMTs, DTFs, and MMTs.
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11 leiomyosarcomas that separated high-grade metastatic tumors from
low-grade ones. More recently, Francis et al. [29] suggest a prognostic
profile modulated at least in part by hypoxia in a large series of highly
malignant soft tissue tumors of mixed types. Using cDNA microarray,
Nakano et al. [30] found seven genes that were differently expressed
between high- and low-grademetastatic sublines of human osteosarcoma
cell lines. Among those genes, five of them (AXL, TGFA, COLL7A1,
WNT5A, and MKK6) were associated with adherence, motility, and/
or invasiveness, suggesting that differences in motility/invasiveness and
adherence are highly involved in the metastatic process in osteosarcoma.
In this same study, proliferative activity showed no obvious correlation
with the metastatic potential.
Among the genes possibly involved in local aggressiveness, SERPIN5
was identified as inhibited in locally aggressive as well as in metastatic
tumors compared with benign tumors. Also known as PCI (protein C
inhibitor), SERPIN5 is known to regulate the activity of the serine
proteases involved in blood coagulation, wound healing, and tumor
metastasis [31,32]. For instance, Wakita et al. [33] demonstrated that
PCI antigen level is significantly lower in renal cell carcinoma (RCC)
tissue than in nontumor kidney tissue, and accordingly, the expression
of PCI messenger RNA was detected in normal renal proximal tubular
epithelial cells but not in RCC or in an RCC cell line (Caki-1 cells).
Also, in vitro invasiveness of Caki-1 cells transfected with a PCI expres-
sion vector was significantly decreased compared with mock-transfected
Caki-1 cells by the addition of anti-PCI.
Protein C inhibitor also inhibits breast cancer cell growth, metastasis,
and angiogenesis independently of its protease inhibitory activity [34].
Urokinase-type plasminogen activator and plasminogen activator
inhibtor-1 (PAT-1) are known to be associated with a poor prognosis
in breast cancer. PAI-3 is expressed in human breast tumors, and elevated
levels of PAI-3 could be a positive prognostic factor in this disease. A
potential mechanism for the contribution of PAI-3 to a positive long-
term outcome may involve suppression of tumor invasion through pro-
tease inhibition in stroma [31]. Hence, our observation that SERPIN5
expression is diminished as a function of tumor aggressiveness corrobo-
rates all these findings and, as suggested by others, its modulation might
be beneficial for local disease control.
MEGF9 (multiple epidermal growth factor [EGF]–like domains) is
a novel transmembrane protein with multiple EGF-like repeats pre-
dominantly expressed in the developing and adults central nervous
system and peripheral nervous system. EGF-like domains are major
modular components present in many proteins of the extracellular
matrix [35]. Mutation in these proteins has been related to several dis-
orders such as Marfan syndrome [36] and leukoencephalopathy [37].
We found a higher expression of EGFL in BMT. This is, to the best
of our knowledge, the first observation suggesting that decreased expres-
sion of MEGF9 in mesenchymal tumors may be associated to tumor
local invasion.
There are very few data about the role of the other three genes dif-
ferentially expressed in local aggressiveness (SNRPD3, AFAP1L2, and
SPTANII/SPETRIN) and cancer. SNRPD3, also known as SMD3, plays
an essential role in the formation of small nuclear ribonucleoprotein
particles by binding to small nuclear RNA and participating in a net-
work of protein interactions [38] and has never been related to cancer
before. AFAP1L2 is an adaptor protein for signal transduction. Down-
regulation ofAFAP1L2 causes a reduction of c-Src activity, IL-8 produc-
tion, EGF-induced phosphorylation of AKT and GSK3β in human
lung epithelial cells, altering the cell cycle [39]. Finally, nonerythroid
α spectrin SPTAN-1 (ALPHA II Spectrin) is shown to be involved
in DNA repair. It is related to tumorigenesis in ovarian cancer [40],
and SPTAN-1 gene was significantly higher in gastric cancer tissue than
in normal gastric mucosa tissue and dysplasia tissue [41].
As for metastatic potential, we identified TOP2A as a gene whose
overexpression was observed in tumors with metastatic potential.
This observation is in agreement with several recent reports including
one by Kozari et al. [42] describing TOP2A as one of the most valuable
markers for aggressive prostate cancer. We also observed overexpression
of UBE2C, a gene frequently found upregulated in tumors with malig-
nant potential and metastasis. Okamoto et al. [43] found a higher
expression of UBE2C in diverse cancer cell lines and primary tumors,
mainly carcinomas, compared with corresponding normal tissues.
Takahashi et al. [44] observed its overexpression in advanced colon can-
cer with liver metastasis. In sarcomas, Arvand et al. [45] demonstrated
that UBE2C is upregulated in NIH3T3 cells transformed with EWS-
FLI1 fusion gene.
MCM2 is a component of the DNA replication licensing complex,
which marks DNA replication origins during G− of cell cycle for use
in subsequent S-phase [46]. An increased expression of MCM2 had
also been reported in several human tumors when compared to the
corresponding nontumor tissue such as hepatocellular carcinoma and
Figure 6. Schematic representation of selected genes based on a dichotomy in their expression profile related to local aggressiveness and
metastatic potential in BMTs, DTFs, and MMTs.
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pancreatic adenocarcinoma [47,48]. Sington et al. [49] showed that
MCM2 is more expressed in myxofibrosarcoma, having a higher histo-
logic grade. Huang et al. [50] also found a relation between increased
expression of MCM2 and adverse prognostic in myxofibrosarcoma.
We also found a higher expression in sarcomas of all types than benign
soft tissue tumors and DTF.
One interesting finding was the overexpression of ARL6IP5 ( JWA)
in tumors without metastatic potential compared with aggressive sarco-
mas. ARL6IP5 ( JWA) codes a microtubule-associated protein that is
essential for the rearrangement of F-actin cytoskeleton and activation
of mitogen-activated protein kinase cascades induced by arsenic trioxide
[51] Therefore, it plays a role in invasion and metastasis. In HeLa, B16,
and HCCLM3 cancer cells, overexpression of JWA, inhibited cellular
migration, and induced deficiency of JWA in HeLa cells implicate
an increase in cell migration [52]. Other studies showed that poly-
morphisms on JWA gene exon 2 was related to leukemia, gastric, esoph-
ageal, and bladder carcinomas [53–55]. Our data suggest that the
down-regulation of JWA by sarcomas may be one of the factors re-
sponsible for the more aggressive behavior and metastatic potential in
soft tissue tumors.
Another gene related with cell migration is ZWINTAS. It is a key
member of the apicobasal Crumbs polarity complex. Cell polarity is
induced and maintained by the separation of the apical and basolateral
domains through specialized cell-cell junctions. The Crumbs protein
and its binding partners are involved in the formation and stabiliza-
tion of adherens junctions [56,57]. Cell polarity is a key process in cell
migration, and ZWINTAS has never been related to tumorigenesis and
tumor behavior before.
Finally, ABCF1 was highly expressed in sarcomas when compared to
BMTs and fibromatosis. This gene is one of the 49 members of human
ATP-binding cassettes transporters. High expression levels of these
transporters have already been reported in several malignant tumors,
including sarcomas, and are related to multidrug resistance [58].
Hence, based on the expression of genes previously identified as
altered, and functionally related to local aggressiveness and metastatic
behavior, our data point to a set of genes with known function but
not previously associated with the biology of mesenchymal tumors. In-
terestingly, the genes described herein were selected based on a di-
chotomy in their expression profile and, as summarized in Figure 6,
seem to acquire altered correlation as the disease progresses as suggested
by Chiang and Massagué [24]. Functionally, an orchestrated balance
among them might be critical for maintaining cellular and tissue ho-
meostasis and, as such, might represent new markers or targets for the
management of sarcomas.
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Table W1. Description of the 102 Samples Used in the c-DNA Microarray and Q-PCR Experiments.
Sample Diagnosis Histologic Grade Category Localization cDNA Microarray Q-PCR
FTS201 Fibroma of tendon sheath NA BMT Finger No Yes
LM45 Leiomyoma NA BMT Cervical Yes Yes
LM46 Leiomyoma NA BMT Pelvic Yes Yes
NF170 Neurofibroma NA BMT Thigh Yes Yes
NF96 Neurofibroma NA BMT Cervical Yes No
NF207 Neurofibroma NA BMT Head No Yes
NF208 Neurofibroma NA BMT Neck No Yes
NF209 Neurofibroma NA BMT Parotid gland No Yes
NF210 Neurofibroma NA BMT Neck No Yes
NF211 Neurofibroma NA BMT Neck No Yes
NF213 Neurofibroma NA BMT Neck No Yes
NF214 Neurofibroma NA BMT Shoulder No Yes
NF215 Neurofibroma NA BMT Orbit No Yes
NF98 Neurofibroma NA BMT Thigh Yes No
SH155 Schwannoma NA BMT Leg Yes No
SH158 Schwannoma NA BMT Retroperitoneum Yes Yes
SH216 Schwannoma NA BMT Leg No Yes
FM165 Desmoid-type fibromatosis NA DTF Thigh Yes No
FM166 Desmoid-type fibromatosis NA DTF Neck Yes No
FM168 Desmoid-type fibromatosis NA DTF Abdominal Yes No
FM193 Desmoid-type fibromatosis NA DTF Thigh Yes No
FM195 Desmoid-type fibromatosis NA DTF Thoracic Yes No
FM196 Desmoid-type fibromatosis NA DTF Abdominal Yes No
FM197 Desmoid-type fibromatosis NA DTF Arm Yes No
FM25 Desmoid-type fibromatosis NA DTF Mandible Yes Yes
FM26 Desmoid-type fibromatosis NA DTF Mandible Yes Yes
FM27 Desmoid-type fibromatosis NA DTF Abdominal Yes No
FM28 Desmoid-type fibromatosis NA DTF Leg Yes Yes
FM29 Desmoid-type fibromatosis NA DTF Thigh Yes No
FM30 Desmoid-type fibromatosis NA DTF Abdominal Yes No
FM31 Desmoid-type fibromatosis NA DTF Thoracic Yes No
FM32 Desmoid-type fibromatosis NA DTF Pelvis Yes No
FM33 Desmoid-type fibromatosis NA DTF Buttock Yes Yes
FM34 Desmoid-type fibromatosis NA DTF Thoracic Yes Yes
FM38 Desmoid-type fibromatosis NA DTF Buttock Yes Yes
FM97 Desmoid-type fibromatosis NA DTF Head and neck Yes Yes
FM202 Desmoid-type fibromatosis NA DTF Abdominal No Yes
FM203 Desmoid-type fibromatosis NA DTF Knee No Yes
FM204 Desmoid-type fibromatosis NA DTF Abdominal No Yes
FM205 Desmoid-type fibromatosis NA DTF Scapular No Yes
FM206 Desmoid-type fibromatosis NA DTF Abdominal No Yes
SA113 Alveolar soft part sarcoma High MMT Head and neck Yes No
SA178 Alveolar soft part sarcoma High MMT Forearm Yes Yes
FS164 Fibrosarcoma High MMT Thigh Yes Yes
FS35 Fibrosarcoma Intermediate MMT Scalp Yes Yes
FS37 Fibrosarcoma High MMT Scapular Yes No
FS39 Fibrosarcoma Low MMT Scapular Yes No
FS40 Fibrosarcoma High MMT Leg Yes Yes
FS41 Fibrosarcoma High MMT Dorsum Yes Yes
GI159 GIST Low MMT Rectum Yes Yes
GI169 GIST Low MMT Stomach Yes Yes
GI43 GIST Low MMT Duodenum Yes No
LES136 Leiomyosarcoma High MMT Orbit Yes No
LES172 Leiomyosarcoma High MMT Prostate Yes No
LES173 Leiomyosarcoma High MMT Uterus Yes Yes
LES182 Leiomyosarcoma High MMT Thigh Yes No
LES48 Leiomyosarcoma Low MMT Pelvis Yes Yes
LES49 Leiomyosarcoma Low MMT Retroperitoneum Yes No
LES51 Leiomyosarcoma Low MMT Thigh Yes No
LES52 Leiomyosarcoma Low MMT Perineum Yes No
LES53 Leiomyosarcoma Intermediate MMT Inguinal region Yes Yes
LES56 Leiomyosarcoma Intermediate MMT Pelvis Yes No
LES57 Leiomyosarcoma Low MMT Mandible Yes No
LES58 Leiomyosarcoma High MMT Vagina Yes Yes
LES59 Leiomyosarcoma High MMT Uterus Yes No
LES60 Leiomyosarcoma High MMT Head and neck Yes Yes
LES61 Leiomyosarcoma High MMT Uterus Yes No
LES62 Leiomyosarcoma High MMT NA Yes No
LES63 Leiomyosarcoma High MMT Uterus Yes No
LES64 Leiomyosarcoma High MMT Retroperitoneum Yes No
LES65 Leiomyosarcoma High MMT Thigh Yes No
LPS75 Lipoblastic liposarcoma Low MMT Retroperitoneum Yes No
TM160 MPNST High MMT Dorsum Yes No
TM179 MPNST Low MMT Head and neck Yes No
Table W1. (continued )
Sample Diagnosis Histologic Grade Category Localization cDNA Microarray Q-PCR
TM194 MPNST Low MMT Head and neck Yes No
TM198 MPNST High MMT Head and neck Yes No
TM200 MPNST Low MMT Leg Yes No
LPS81 Myxoid liposarcoma Low MMT Leg Yes No
LPS89 Myxoid liposarcoma Low MMT Thigh Yes No
SP122 Pleomorphic sarcoma High MMT Forearm Yes Yes
SP124 Pleomorphic sarcoma High MMT Mandible Yes No
SP125 Pleomorphic sarcoma High MMT Retroperitoneum Yes Yes
SP126 Pleomorphic sarcoma High MMT Thigh Yes Yes
SP127 Pleomorphic sarcoma High MMT Skin/breast Yes Yes
SP131 Pleomorphic sarcoma High MMT Neck Yes Yes
SP132 Pleomorphic sarcoma High MMT Leg Yes No
SP134 Pleomorphic sarcoma High MMT Retroperitoneum Yes No
SP135 Pleomorphic sarcoma High MMT Retroperitoneum Yes No
SP138 Pleomorphic sarcoma High MMT Thigh Yes No
SP161 Pleomorphic sarcoma High MMT Mandible Yes No
SP174 Pleomorphic sarcoma High MMT Arm Yes No
SP175 Pleomorphic sarcoma High MMT Thigh Yes No
SP186 Pleomorphic sarcoma High MMT Arm Yes No
SP188A Pleomorphic sarcoma High MMT Thigh Yes No
SP190A Pleomorphic sarcoma High MMT Thigh Yes No
SP191 Pleomorphic sarcoma High MMT Buttock Yes No
LPS68 Round cell liposarcoma High MMT Thigh Yes No
LPS137 Round cell liposarcoma High MMT Thigh Yes No
SS140 Synovial sarcoma High MMT Thigh Yes Yes
SS142 Synovial sarcoma High MMT Thigh Yes No
SS143 Synovial sarcoma High MMT Thigh Yes Yes
SS144 Synovial sarcoma High MMT Elbow Yes No
SS145 Synovial sarcoma High MMT Arm Yes No
SS147 Synovial sarcoma High MMT Leg Yes No
SS148 Synovial sarcoma High MMT Arm Yes No
SS149 Synovial sarcoma High MMT Arm Yes No
SS152 Synovial sarcoma High MMT Inguinal Yes No
SS153 Synovial sarcoma High MMT Arm Yes No
SS154 Synovial sarcoma High MMT Head and neck Yes No
SS157 Synovial sarcoma High MMT Elbow Yes No
SS162 Synovial sarcoma High MMT Thigh Yes No
SS176 Synovial sarcoma High MMT Thigh E Yes No
SS177 Synovial sarcoma High MMT Paraspinal Yes Yes
SS183 Synovial sarcoma High MMT Knee Yes No
SS192 Synovial sarcoma High MMT Hand Yes No
SS199 Synovial sarcoma High MMT Leg Yes No
SS36 Synovial sarcoma High MMT Thigh Yes No
Table W2. Primer Sets Used in Q-PCR Experiment.
Gene Name Primers Sequence Amplicon Length (bp)
AFAP1 5′-GGTCGTGGTCACAGGCAAA-3′ 63
5′-GCTCCTTTCTTCTCCCATTCCT-3′
ENDOD 5′-CTGGTGGAGCCGCAGATC-3′ 64
5′-GGCCTCTGCCTCATTAATCG-3′
MEGF 5′-GTTCACGACCTCGAGGGAAA-3′ 65
5′-GTAGAACCTTCAGGTGTTGGAAGAA-3′
SERPIN 5′-TCTGTCCGGCATCAGCAA-3′ 62
5′-CCACAGCTTTGTGCACCATCT-3′
MCM2 5′-CACACAGAAGTTCAGCGTCATG-3′ 60
5′-AATGAAAGGTAGCGGGCAAA-3′
TOP2A 5′-CCTAAAAAGAATGTGACAGTGAAGAAGA-3′ 65
5′-CCGGTAGTGGAGGTGGAAGA-3′
UBE2E 5′-GCCGAGCTCTGGAAAAACC-3′ 64
5′-CTGGTGACCTGCTTTGAGTAGGT-3′
ZWINTAS 5′-TGGAGGACAGCAGCATGGA-3′ 61
5′-TTGGGAGGTGAGGGAAGTCA-3′
SNRPD3 5′-TGGAGGACAGCAGCATGGA-3′ 75
5′-TTGGGAGGTGAGGGAAGTCA-3′
SPTAIN1 5′-GCTCAGAGGGAAAGCCTTACG-3′ 63
5′-CTTGTTCCCGGGTCAGGTT-3′
ABCF1 5′-CACGCCCACACCATCCA-3′ 57
5′-CACAACTCGCGCCTTCTGA-3′
ARL61P5 5′-TGGAGGAGTCATGGTCTTTGTG-3′ 67
5′-CGATGCATGGATAAACATCAACA-3′
Table W3. Complete List with Fold Change and Corrected P Values of All Genes Are Available at
http://www.maiges.org/sarcomaFibromatosis/.
Figure W1. Representativebox plot showing the expression (fold change) of the six genes related to local aggressiveness (AFAP1L2,MEGF9,
ENDOD1, SERPIN5, SNRPD3, and SPTAN; and the six genes related to metastatic potential (ABCF1,MCM2, ARL6IP5, TOP2A, UBE2C, and
ZWINTAS; in BMTs, DTFs, and low-, intermediate-, and high-grade sarcomas. For all genes, the value for each pairwise comparison is de-
scribed in Table W3.
Figure W1. (continued ).
